Skip to main content

Mumps

8
Pipeline Programs
8
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
4
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
2100%
+ 15 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
5 programs
1
1
1
Measles, Mumps, Rubella and ChickenpoxPhase 4
Measles, Mumps, Rubella and ChickenpoxPhase 3
MeMuRu-OKAPhase 2
Botulinum Toxin Type AN/A
Priorix-Tetra™N/A
Sinovac Biotech
Sinovac BiotechChina - Beijing
2 programs
1
1
Mumps vaccine, LivePhase 4Vaccine1 trial
Investigational live attenuated mumps vaccinePhase 3Vaccine1 trial
Active Trials
NCT05065177Completed1,140Est. Apr 2016
NCT06208683Unknown400Est. Dec 2024
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
MMR booster vaccinationPhase 3
MSD
MSDIreland - Ballydine
1 program
1
MMR booster vaccinationPhase 31 trial
Active Trials
NCT05894395Unknown200Est. Sep 2025
CyanVac
CyanVacGA - Athens
1 program
1
CVM150Phase 11 trial
Active Trials
NCT06967181Active Not Recruiting60Est. Dec 2027
GSK
GSKLONDON, United Kingdom
5 programs
Botulinum Toxin Type AN/A1 trial
Priorix-Tetra™N/A1 trial
MeMuRu-OKAPHASE_21 trial
Measles, Mumps, Rubella and ChickenpoxPHASE_31 trial
Measles, Mumps, Rubella and ChickenpoxPHASE_41 trial
Active Trials
NCT01390922Completed1,038Est. Oct 2014
NCT01738841Withdrawn0Est. Mar 2016
NCT00352898Completed400Est. Nov 2006
+2 more trials
Biocorp
BiocorpFrance - Issoire
1 program
MMRN/A1 trial
Active Trials
NCT01874457Completed150Est. Aug 2009
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
MMR booster vaccinationPHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Sinovac BiotechMumps vaccine, Live
GSKMeasles, Mumps, Rubella and Chickenpox
MSDMMR booster vaccination
Sinovac BiotechInvestigational live attenuated mumps vaccine
GSKMeasles, Mumps, Rubella and Chickenpox
GSKMeMuRu-OKA
CyanVacCVM150
GSKPriorix-Tetra™
GSKBotulinum Toxin Type A
BiocorpMMR

Clinical Trials (10)

Total enrollment: 5,771 patients across 10 trials

NCT06208683Sinovac BiotechMumps vaccine, Live

The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students

Start: Nov 2023Est. completion: Dec 2024400 patients
Phase 4Unknown
NCT00126997GSKMeasles, Mumps, Rubella and Chickenpox

Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Start: May 2005Est. completion: Nov 20051,439 patients
Phase 4Completed
NCT05894395MSDMMR booster vaccination

Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination

Start: Dec 2023Est. completion: Sep 2025200 patients
Phase 3Unknown
NCT05065177Sinovac BiotechInvestigational live attenuated mumps vaccine

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants

Start: Jan 2016Est. completion: Apr 20161,140 patients
Phase 3Completed
NCT00127023GSKMeasles, Mumps, Rubella and Chickenpox

Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Start: May 2005Est. completion: Nov 2005944 patients
Phase 3Completed
NCT00352898GSKMeMuRu-OKA

Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

Start: Apr 2006Est. completion: Nov 2006400 patients
Phase 2Completed
NCT06967181CyanVacCVM150

A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults

Start: May 2025Est. completion: Dec 202760 patients
Phase 1Active Not Recruiting
NCT01738841GSKPriorix-Tetra™

Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines

Start: Aug 2013Est. completion: Mar 20160
N/AWithdrawn
NCT01390922GSKBotulinum Toxin Type A

Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.)

Start: Aug 2011Est. completion: Oct 20141,038 patients
N/ACompleted
NCT01874457BiocorpMMR

Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)

Start: May 2008Est. completion: Aug 2009150 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.